Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Autor:	Lordick, F., Mauer, M.E., Stocker, G., Cella, C.A., Ben-Aharon, I., Piessen, G., Wyrwicz, L., Al-Haidari, G., Fleitas-Kanonnikoff, T., Boige, V., Lordick Obermannová, R., Martens, U.M., Gomez-Martin, C., Thuss-Patience, P., Arrazubi, V., Avallone, A., Shiu, K.K., Artru, P., Brenner, B., Buges Sanchez, C., Chau, I., Lorenzen, S., Daum, S., Sinn, M., Merelli, B., van Grieken, N.C.T., Nilsson, M., Collienne, M., Giraut, A., Smyth, E.
Zdroj:	In Annals of Oncology
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu